Can global contract research organisations contribute to decarbonisation? The impact of environmentally sustainable business practice on scope 1 and 2 emissions

Carbon emissions of clinical trials have been one of the contributors to global emissions. However, the clinical research industry, particularly contract research organisations (CROs) engaged in trials, has received little attention in the existing literature regarding their carbon footprint. This research examines the sustainable practices implemented by leading global CROs and how these practices influence scope 1 and 2 CO2 emissions. The findings show that increasing the number of sustainability initiatives is insufficient to achieve a measurable reduction in emissions. At the same time, whilst some sustainable practices, such as building upgrades and real estate improvements, lead to a reduction in scope 1 and 2 emissions, others, such as equipment upgrades, are associated with higher emissions. The study, therefore, uncovers a counterintuitive finding—that renewable energy practices showed a positive correlation with emissions. This may be viewed as a paradox, although it serves as a critical warning against measuring sustainability by the quantity of initiatives, rather than their quality or ultimate effect. By assessing the impact of organisational environmental practices on emissions, the study contributes to knowledge by providing a more nuanced understanding of the effectiveness of environmentally sustainable business strategies adopted by CROs.